Sanzyme Biologics Private Limited, based in Hyderabad, Telangana, India, is a pioneering manufacturer and innovator in the field of probiotics, serving a wide range of industries including food, pharmaceuticals, aquaculture, veterinary health, agriculture, and environmental applications. With over five decades of biotech experience and a legacy rooted in India’s pharmaceutical development, Sanzyme Biologics has evolved into a global provider of clinically validated, commercially viable probiotic strains and microbial technologies. ## Core Business and Offerings Sanzyme Biologics specializes in the research, development, fermentation, and commercialization of probiotics. Their offerings are designed to cater to both B2B ingredient supply and B2C finished formulations across human and animal health markets. ### Key Product Segments: - Human Health Probiotics - Proprietary and patented strains for use in food, beverages, dietary supplements, and pharmaceuticals. - Probiotic Oral Suspensions and Capsules - SNZ 1969® – the company’s flagship Bacillus coagulans strain with extensive clinical validation. - Animal Health Solutions - Pet Food Probiotics: Designed to improve digestion and immunity in companion animals. - Poultry Solutions: Applied via feed (pellets/mash), water, spray, and litter management for gut health, pathogen control, and bioremediation. - Aquaculture and Marine Solutions - Probiotics for water and soil management in fish and shrimp farms. - Feed additives, ammonia reducers, mineral supplements, hatchery probiotics, and sanitizers. - Environmental and Agricultural Applications - Microbial solutions for soil enrichment, organic farming, and waste remediation. - Contract Manufacturing and R&D Services - CDMO services for fermentation-based ingredient development and end-product manufacturing. - Application and stability testing for global regulatory markets. ## Specialization and Unique Strengths Sanzyme Biologics is distinguished by its expertise in spore-forming probiotic strains, stability under harsh conditions, and broad regulatory acceptance. - Proprietary Strains: SNZ 1969® (Bacillus coagulans) is one of the most clinically studied and globally accepted spore-forming strains. - Global Regulatory Approvals: Strains registered and approved in USA (GRAS), Canada (NNHPD), EU (EFSA QPS), Japan, Korea, and Australia (TGA). - Shelf-Stable Formulations: Designed to remain active in ambient storage and withstand harsh processing conditions (e.g., baking, extrusion). - Multifunctional Applications: Solutions tailored for functional foods, animal feed, pharma-grade probiotics, and environmental resilience. ## Financials and Export Insights Sanzyme Biologics is a privately held entity with significant export activity and R&D investment. Key performance insights include: - According to Panjiva and ImportGenius, the company has exported to over 35 countries, including: - USA - Germany - Canada - Japan - South Korea - Australia - Vietnam - Brazil - Export volumes of SNZ 1969® and contract-manufactured probiotic blends have grown at a CAGR of 18–20% over the last four years. - Participation in international exhibitions such as Vitafoods Europe, CPHI Worldwide, and Fi Asia highlights its global market engagement. ## Target Markets Sanzyme Biologics provides customized solutions for diverse industries: - Nutraceutical and Pharmaceutical Companies - Functional Food and Beverage Manufacturers - Veterinary and Pet Care Brands - Aquaculture and Livestock Feed Suppliers - Agricultural and Environmental Tech Providers - Nutritional Research Institutions and CDMO Clients Its strains are widely used in finished dosage forms like capsules, sachets, chewables, powders, and effervescents. ## Capabilities and Infrastructure The company’s manufacturing and research capabilities are rooted in over 50 years of fermentation expertise. Infrastructure includes: - WHO-GMP certified production facilities - Dedicated spore-forming probiotic fermentation plants - In-house QA/QC labs with stability, potency, and microbiological testing - State-of-the-art R&D center focusing on strain isolation, characterization, and clinical trials - Customized formulation and packaging lines for global partners Annual production capacity exceeds 300 metric tons of probiotic biomass, with scalability across ingredient and finished dosage forms. ## Certifications and Compliance Sanzyme Biologics maintains a globally compliant quality and regulatory framework: - WHO-GMP Certification - FSSAI Approved - US-FDA Registered - GRAS Status for Key Strains - EU EFSA QPS (Qualified Presumption of Safety) - Health Canada NNHPD Approved - TGA (Australia) Compliant - ISO 22000, HACCP, and Halal Certified These certifications enable the company to support full regulatory dossiers for global clients. ## Testimonials and Industry Recognition Sanzyme Biologics has received consistent recognition from industry partners and international regulatory reviewers. A nutraceutical formulator in North America remarked: > “Sanzyme’s SNZ 1969® is one of the most versatile and reliable probiotic strains we’ve used—clinically backed, shelf-stable, and supported by exceptional technical service.” The company has also been featured in Nutraceutical Business Review, Probiotics Institute, and Food Ingredients First for its contributions to spore-forming probiotic science. ## Major Achievements - Commercialized SNZ 1969®, one of the world’s first clinically validated Bacillus coagulans strains - Exported probiotic ingredients to over 35 countries - Developed probiotic formulations for aquaculture, poultry, and pet segments - Partnered with international CDMOs and supplement brands for white-label probiotic products - Invested in proprietary research and IP around spore-forming probiotics and gut microbiota modulation Sanzyme Biologics continues to drive innovation in microbial biotechnology with a strong scientific foundation, global compliance, and a solutions-oriented approach to probiotics across industries.
